Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer.

Abstract: The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer.

Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.

Abstract: The present invention relates to protein conjugates comprising an aprotinin-derived polypeptide, which facilitates transport of the conjugate across the blood-brain barrier, and an antibody moiety that selectively binds a target within the CNS. The protein conjugates are further defined by the inclusion of a linker; by the number of polypeptides conjugated to each antibody moiety; by the positions at which the antibody moiety and the polypeptides are conjugated; and by the larger configuration of the conjugate (in which every polypeptide is linked only to the antibody moiety). Modified aprotinin-derived polypeptides, linker-bound antibody moieties, pharmaceutical compositions, kits, and methods of making and using the protein conjugates are also features of the invention.

Abstract: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, a compound that includes iduronate-2-sulfatase conjugated to Angiopep-2 through a linker formed by specific click chemistry reactions. In certain embodiments, these compounds, owing to the presence of the targeting moiety, can cross the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features pharmaceutical compositions containing such compounds and methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.

Abstract: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.

Abstract: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.

Abstract: Disclosed herein is the preparation of reaction products which contain carboxylic acid-grafted functionalized propylene homopolymers and copolymers that can be used as additives for polyolefin-based plastic products such as hot melt adhesives. Such reaction product additives may be prepared by: a) providing a first reactant comprising a selected type of relatively low molecular weight, low melt viscosity, molten propylene-based homopolymer or copolymer; b) forming a reaction mixture by adding to this first reactant a second reactant comprising an unsaturated carboxylic acid-based functionalizing agent, and an initiator comprising a certain type of organic peroxide; and c) maintaining the resulting reaction mixture at a relatively low temperature between about 130° C. and about 165° C. for a period of time and under conditions sufficient to form a reaction product which comprises acid-grafted propylene-based polymeric material, and which has a relatively high Grafting Efficiency.

Abstract: Compositions are provided having from 70 wt % to 95 wt % of a polymer selected from homopolymers and random copolymers of propylene and from 5 wt % to 30 wt % of a miscible hydrocarbon resin with a glass transition temperature greater than 20° C. The polymer has a heat of fusion of less than 50 J/g, a melt index (MI) of less than 20 dg/min, and contains stereoregular propylene crystallinity. Also provided are films containing such compositions, and articles, such as diapers or incontinence garments, including such films.

Abstract: An embossable film for creating holograms and diffraction gratings and methods of producing the embossable films are provided. The embossable film includes a base layer and a co-extruded embossable layer that is coated with a transparent high refractive index (HRI) coating prior to embossing.